First-in-class covalent BTK (Bruton tyrosine kinase) inhibitor — irreversible Michael acceptor that binds Cys481 in the BTK ATP pocket. Indications: CLL/SLL, mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, cGVHD. Strong CYP3A4 substrate (F ~3%; raising it to ~10% with mild inducers, contraindicated with strong inhibitors due to risk of atrial fibrillation + bleeding). Off-target effects on EGFR, ITK, TEC, HER2 account for the rash + diarrhea + AF profile. PK (Imbruvica label, SS 560 mg PO qd): AUC 953 ± 705 ng·h/mL, t½ 4-6 h, Tmax 1-2 h, absolute F 2.9% fasted (doubles to ~6% with food — administration with food recommended). Apparent V/F ~4200 L; true Vd ~122 L. CYP3A4 substrate; massive food effect + strong inducer/inhibitor sensitivity.
Half-Life & Elimination Curve (PO: 5h)
Plasma (PO)t½ Decay (5h)
0×t½0h100%(69.1 µg/L)
1×t½5h50%(34.6 µg/L)
2×t½10h25%(17.3 µg/L)
3×t½15h12.5%(8.64 µg/L)
4×t½20h6.3%(4.32 µg/L)
5×t½25h3.1%(2.16 µg/L)
Elimination t½5h (PO)
Rate Constant (ke)0.139 h⁻¹
Time to Peak (Tmax)2.65h
Est. Peak (Cmax)69.1 µg/L
Clearance (CL)16.9 L/h
97% Washout (5×t½)25h
Dosing Guidelines
Oral (PO): Typical 420 mg (Range: 140–560 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 2.9% · Volume of Distribution (Vd): 122 L · Absorption (ka): 0.8 h⁻¹ (t½ka ≈ 52m)